Atrial Fibrillation Clinical Trial
— OPTIMALOfficial title:
Evaluation of the Precision and Accuracy of International Normalised Ratio (INR) Measurements as Assessed by the LumiraDx Instrument in a Professional Point of Care Setting With Multiple Operators
Verified date | September 2018 |
Source | LumiraDx UK Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and assessment of accuracy and bias by regression analysis and other analytical methods.
Status | Completed |
Enrollment | 420 |
Est. completion date | November 23, 2018 |
Est. primary completion date | November 23, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria - VKA Therapy Subjects: - Persons >18 years of age - Willing and able to provide written informed consent and comply with study procedures - Currently prescribed vitamin K antagonist therapy - Deemed medically appropriate for study participation by the Investigator Exclusion Criteria - VKA Therapy Subjects: - Persons <18 years of age - Subject has previously participated in this study - Subject is within 4 weeks of first prescription of vitamin K antagonist therapy - Confirmed or suspected pregnancy - Unwilling or unable to provide written informed consent and comply with study procedures - Vulnerable populations deemed inappropriate for study by the Investigator - Deemed medically inappropriate for study by the Investigator (i.e. patients with a known inherited [e.g. haemophilia or von Willebrand's disease] or acquired [e.g. liver cirrhosis] condition likely to be associated with a coagulopathy; or patients receiving non-VKA anticoagulant medications) Inclusion Criteria - Non-VKA Therapy Subjects: - Persons >18 years of age - Willing and able to provide written informed consent and comply with study procedures - Deemed medically appropriate for study participation by the Investigator Exclusion Criteria - Non-VKA Therapy Subjects: - Persons <18 years of age - Subject has previously participated in this study - Confirmed or suspected pregnancy - Unwilling or unable to provide written informed consent and comply with study procedures - Vulnerable populations deemed inappropriate for study by the Investigator - Any persons deemed medically inappropriate for study by the Investigator |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Glasgow Royal Infirmary Clinical Research Facility | Glasgow | |
United Kingdom | Golden Jubilee National Hospital | Glasgow | |
United Kingdom | Wishaw General Hospital, NHS Lanarkshire | Wishaw |
Lead Sponsor | Collaborator |
---|---|
LumiraDx UK Limited |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the clinical performance of the LumiraDx instrument | Measurement of INR using Capillary & Venous blood samples | 8 weeks | |
Secondary | To determine the accuracy of the LumiraDx instrument | Measurement of INR & Haematocrit using Capillary & Venous blood samples | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |